All of the newly diagnosed glioblastoma multiforme patients enrolled in a Phase 1 clinical trial have exceeded both their median and expected progression-free survivals. Two patients, to date, have exceeded their expected overall survival.

This therapy, using sustained release of nitric oxide, may be a novel, efficient and safe way to prevent and treat multiple metabolic diseases.

The monoclonal antibody cocktail is deliverable via a nasal dose, and it is also effective against SARS, MERS and several coronavirus cold viruses. The antibodies are engineered for long-acting effectiveness, potentially lasting a year or more when used in humans.

Collective strength of the research enterprise leads to almost $849 million in research grants and awards for FY 2021.

The life sciences fund will focus on development of early-stage UAB technologies and startup companies.

UAB professors publish distinct conceptual framework for entrepreneurship in educational settings.